Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Clinician's Roundtable
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Shelina Ramnarine, PhD; David A. Johnson, MD, FACG, FACP
- Shelina Ramnarine, PhD
- David A. Johnson, MD, FACG, FACP
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Project Oncology®
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
CME/CE Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
1.00 credit
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Medical News

Medical News
More Negative Sentinel Nodes Didn’t Improve Breast Cancer Outcomes
09/04/2026
Read more
Medical News
Real-World ALK TKI Outcomes in Metastatic NSCLC
09/04/2026
Read more
Medical News
Predicting Pneumonia After Brain Tumor Surgery
09/04/2026
Read more
Medical News
Fruit, Vegetables and NMIBC Recurrence Risk
09/04/2026
Read more

CME/CE

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CE
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
1.00 credit
- Sagar Lonial, MD, FACP
1.00 credit
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CE
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS; Ghayas Issa, MD
0.50 credits
- Amer Zeidan, MBBS
- Ghayas Issa, MD
0.50 credits

Clinical Practice

Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Clinician's Roundtable
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Peter Buch, MD, FACG, AGAF, FACP; Mallik Greene, PhD
- Peter Buch, MD, FACG, AGAF, FACP
- Mallik Greene, PhD
- Jordan Karlitz, MD
MinuteCE®
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Project Oncology®
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
- Lajos Pusztai, MD, DPhil
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD; Mohamed Abdelbaki, MD
- Shelina Ramnarine, PhD
- Mohamed Abdelbaki, MD

Programs

Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Project Oncology®
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Wassim Mchayleh, MD, MBA, FACP
- Charles Turck, PharmD, BCPS, BCCCP
- Wassim Mchayleh, MD, MBA, FACP
Supporting Patients Throughout Urothelial Carcinoma Treatment
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD